Literature DB >> 8842049

Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies.

R A Morrison1, S Chong, A M Marino, M A Wasserman, P Timmins, V A Moore, W J Irwin.   

Abstract

PURPOSE: Previous in situ and in vitro studies indicated that the intestinal absorption of enalapril is a saturable carrier-mediated process via the dipeptide transporter system (DTS); however, the oral absorption of enalapril has not been reported to be a saturable process in vivo. Our objectives were to: 1) evaluate the suitability of enalapril as a probe of the DTS, and 2) compare various experimental models as they pertain to studying the DTS.
METHODS: The in vitro uptake of enalapril by rat intestinal rings and permeability across Caco-2 cells were studied as a function of concentration and in the presence of compounds that are known substrates of the DTS. The effect of enalapril on the uptake of [3H]-glycyl-L-proline (gly-L-pro) by Caco-2 cells was also examined. In vivo studies were conducted in rats (1 to 50 mg/kg) and dogs (0.06 to 6 mg/kg) to evaluate the oral absorption of enalapril over a wide dose range.
RESULTS: In vitro intestinal uptake/permeability of enalapril was not saturable nor inhibited by beta-lactam antibiotics, gly-L-pro, or SQ-29852. Moreover, a 20,000-fold molar excess of enalapril did not inhibit the uptake of [3H]-gly-L-pro by Caco-2 cells. The in vivo studies in rats and dogs did not demonstrate saturable absorption.
CONCLUSIONS: The present in vitro and in vivo results indicated that enalapril is primarily absorbed by a non-saturable, passive diffusion process and it is not a suitable model compound for studying the DTS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842049     DOI: 10.1023/a:1016071027177

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ-29852.

Authors:  A M Marino; S Chong; S A Dando; K J Kripalani; M S Bathala; R A Morrison
Journal:  J Pharm Sci       Date:  1996-03       Impact factor: 3.534

2.  In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system.

Authors:  S Chong; S A Dando; K M Soucek; R A Morrison
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

3.  Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.

Authors:  A H Dantzig; L Bergin
Journal:  Biochim Biophys Acta       Date:  1990-09-07

4.  Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2).

Authors:  M Hu; J Chen; Y Zhu; A H Dantzig; R E Stratford; M T Kuhfeld
Journal:  Pharm Res       Date:  1994-10       Impact factor: 4.200

5.  Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.

Authors:  D I Friedman; G L Amidon
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

6.  Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852.

Authors:  D I Friedman; G L Amidon
Journal:  J Pharm Sci       Date:  1989-12       Impact factor: 3.534

7.  Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells.

Authors:  A H Dantzig; D C Duckworth; L B Tabas
Journal:  Biochim Biophys Acta       Date:  1994-04-20

8.  Noncompetitive inhibition of cephradine uptake by enalapril in rabbit intestinal brush-border membrane vesicles: an enalapril specific inhibitory binding site on the peptide carrier.

Authors:  H Yuasa; D Fleisher; G L Amidon
Journal:  J Pharmacol Exp Ther       Date:  1994-06       Impact factor: 4.030

9.  Contribution of passive transport mechanisms to the intestinal absorption of beta-lactam antibiotics.

Authors:  M Sugawara; H Saitoh; K Iseki; K Miyazaki; T Arita
Journal:  J Pharm Pharmacol       Date:  1990-05       Impact factor: 3.765

10.  Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells.

Authors:  D T Thwaites; M Cavet; B H Hirst; N L Simmons
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  10 in total
  3 in total

1.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and age-dependent differences in absorption.

Authors:  Eva J Streekstra; Márton Kiss; Jeroen van den Heuvel; Johan Nicolaï; Petra van den Broek; Sanne M B I Botden; Martijn W J Stommel; Lara van Rijssel; Anna-Lena Ungell; Evita van de Steeg; Frans G M Russel; Saskia N de Wildt
Journal:  Clin Transl Sci       Date:  2022-08-12       Impact factor: 4.438

3.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.